Royalty Pharma plc (NASDAQ:RPRX) said it has entered into a research and development co-funding agreement with Johnson & Johnson (NYSE:JNJ) valued at $500 million to support the development of JNJ-4804, an experimental treatment for autoimmune diseases. The funding will be provided over the 2026–2027 period.
JNJ-4804 is described as a novel co-antibody therapy designed to inhibit both the interleukin-23 and tumor necrosis factor pathways, targeting chronic immune-mediated disorders. The therapy aims to generate synergistic effects in addressing the underlying mechanisms of these diseases.
“We are delighted to collaborate with Johnson & Johnson on the clinical development of JNJ-4804,” said Pablo Legorreta, Chief Executive Officer and Chairman of Royalty Pharma. “Royalty Pharma has a strong track record of investing in immunology, beginning with early disease-modifying biologics including TNF inhibitors.”
Legorreta added that Johnson & Johnson is widely recognized for its leadership in immunology and said he believes JNJ-4804 has significant potential for patients suffering from chronic immune-mediated conditions. He described the partnership as another step in Royalty Pharma’s strategy of collaborating with major global biopharmaceutical companies.
Founded in 1996, Royalty Pharma describes itself as the largest acquirer of biopharmaceutical royalties. Its portfolio includes royalty interests tied to more than 35 marketed medicines and 19 product candidates currently in development, according to the company.
Law firm Goodwin Procter LLP acted as legal adviser to Royalty Pharma on the transaction. The details of the agreement were disclosed in a company press release.